

# Early-Onset Type-2 Diabetes in Adolescents

Marco Russo\*

Department of Clinical Medicine, University of Naples, Italy

## Corresponding Author\*

Marco Russo

Department of Clinical Medicine, University of Naples, Italy

E-mail: russomr@researchcentre.com

**Copyright:** © 2024 Russo M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Received:** 01-July-2024, Manuscript No. jdm-24-33642; **Editor assigned:** 03-July-2024, PreQC No. jdm-24-33642; **Reviewed:** 17-July-2024, QC No. jdm-24-33642; **Revised:** 21-July-2024, Manuscript No. jdm-24-33642; **Published:** 28-July-2024, DOI: 10.35248/2155-6156.10001146

## Abstract

Type-2 diabetes (T2D) in adolescents has emerged as a significant public health concern, driven by the global rise in obesity and sedentary lifestyles among youth. This article explores the increasing prevalence, underlying causes, and the clinical and psychosocial impact of T2D in adolescents. The study delves into the pathophysiology of the disease, emphasizing insulin resistance and  $\beta$ -cell dysfunction. It also examines the challenges in managing T2D in this age group, including adherence to treatment regimens, lifestyle modifications, and the potential long-term complications. The findings highlight the need for early intervention, comprehensive education, and multidisciplinary approaches to curb the growing burden of T2D in adolescents.

**Keywords:** Type-2 diabetes; Adolescents; Insulin resistance; Obesity;  $\beta$ -cell dysfunction; Lifestyle intervention; Public health; Long-term complications

## Introduction

The rising incidence of Type-2 diabetes (T2D) among adolescents has become a critical public health issue. Traditionally considered a disease of adults, T2D is now increasingly diagnosed in younger populations, correlating with the global epidemic of obesity and sedentary behaviours. This shift has profound implications for the health and well-being of affected adolescents, as they face the dual burden of managing a chronic condition during a formative stage of life and the risk of early-onset complications. Understanding the factors contributing to this trend and the unique challenges faced by this demographic is essential for developing effective prevention and management strategies [1,2].

## Type-2 diabetes in adolescents

Addressing Type-2 diabetes in adolescents is crucial due to its rapidly increasing prevalence, which mirrors rising obesity rates and sedentary lifestyles in youth. Early-onset diabetes predisposes adolescents to severe complications, such as cardiovascular disease, kidney failure, and neuropathy, much earlier in life, leading to a significant reduction in life expectancy and quality of life. The broader public health implications include an increased burden on healthcare systems, with higher costs associated with managing chronic complications over extended periods. Moreover, the psychosocial impact on affected adolescents underscores the urgent need for comprehensive prevention, early intervention, and targeted public health strategies [3,4].

## Impact on long-term health

Adolescents with Type-2 diabetes face a heightened risk of developing serious long-term health complications, including cardiovascular disease, nephropathy, retinopathy, and neuropathy, often at a younger age compared to those with Type 1 diabetes or adults with T2D. The aggressive nature of the disease in youth, coupled with challenges in maintaining optimal glycemic control, accelerates the progression of these complications. Additionally, the psychological burden, including increased rates of depression and anxiety, significantly impacts quality of life. Early and effective management is crucial to mitigate these long-term health risks and improve overall outcomes for affected adolescents [5,6].

## Description

Type-2 diabetes in adolescents is primarily characterized by insulin resistance and a progressive decline in  $\beta$ -cell function. The pathophysiology of T2D in this age group mirrors that in adults but is often more aggressive, leading to a rapid progression of the disease and an earlier onset of complications. Adolescents with T2D often present with obesity, acanthosis nigricans, polycystic ovary syndrome (PCOS) in females, and a family history of diabetes. The lifestyle factors contributing to the development of T2D in adolescents include poor dietary habits, physical inactivity, and increased screen time, all of which promote obesity. Additionally, genetic predisposition plays a significant role, with certain ethnic groups, such as African American, Hispanic, Native American, and Asian populations, being at higher risk [7,8].

Managing T2D in adolescents is challenging due to the unique psychological, social, and developmental factors at play. Adolescents often struggle with adherence to medication and lifestyle changes, which are crucial for managing the disease. Moreover, the stigma associated with obesity and diabetes can lead to psychological distress, further complicating management efforts. The treatment approach typically involves lifestyle interventions aimed at weight reduction, dietary modifications, and increased physical activity, along with pharmacological therapies such as metformin and, in some cases, insulin [9].

## Results

Studies indicate that adolescents with T2D are at a higher risk of developing complications such as cardiovascular disease, kidney dysfunction, retinopathy, and neuropathy at a younger age compared to those with Type 1 diabetes or adults with T2D. Longitudinal studies have shown that the rapid progression of these complications is often due to suboptimal glycemic control and the challenges in sustaining long-term lifestyle modifications. Additionally, the psychological impact of T2D on adolescents, including increased rates of depression and anxiety, significantly affects their quality of life and disease outcomes [10].

## Conclusion

The increasing prevalence of Type-2 diabetes in adolescents represents a significant challenge to public health. Early diagnosis, effective management, and prevention strategies are crucial to mitigate the long-term health consequences of this disease. A multidisciplinary approach, involving healthcare providers, educators, families, and communities, is essential to address the complex needs of adolescents with T2D. Interventions should focus not only on medical management but also on psychosocial support to improve adherence and outcomes. Public health initiatives aimed at reducing obesity and promoting healthy lifestyles among youth are vital in reversing the upward trend of Type-2 diabetes in adolescents.

## References

1. Cersosimo E, Miles JM (2019) Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria In Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors. *Curr Diabetes Rev* 15: 314-327.

2. Awad AK, Hasan TM, Shih M, Attia AN, Aboeldahab H, et al. (2022) Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials. *European Heart Journal* 43: 941.
3. Podestà MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M (2023) SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. *Biomedicines* 11: 279.
4. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, et al. (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 375: 311-322.
5. Marso SP, Brian SC, Consoli A, Eliaschewitz FG, Jodar E, et al. (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 375: 1834-1844.
6. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, et al. (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. *Lancet* 394: 121-130.
7. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, et al. (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. *Lancet* 392: 1519-1529.
8. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, et al. (2017) Effects of once weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 377: 1228-1239.
9. Mann JFE, Ørsted DD, Buse JB (2017) Liraglutide and Renal Outcomes in Type 2 Diabetes. *N Engl J Med* 377: 2197-2198.
10. Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, et al. (2018) Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: An exploratory analysis of the ELIXA randomized, placebo-controlled trial. *Lancet Diabetes Endocrinol* 6: 859-869.